Efficacy and Physiology of Nasal High Flow Therapy

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DEVICE

NHF therapy

AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.

OTHER

Long term Oxygen Therapy (LOT)

Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.

Trial Locations (1)

58091

Helios Klinik Ambrock, Hagen

All Listed Sponsors
collaborator

Fisher and Paykel Healthcare

INDUSTRY

lead

Institut für Pneumologie Hagen Ambrock eV

INDUSTRY

NCT02083120 - Efficacy and Physiology of Nasal High Flow Therapy | Biotech Hunter | Biotech Hunter